Acadia outlines 2026 revenue target up to $1.28B while advancing DAYBUE STIX and NUPLAZID growth
Earnings Call Insights: ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Catherine Owen Adams, CEO, highlighted a milestone year,...
Tag: ACAD
Acadia Pharma GAAP EPS of $1.60 beats by $1.46, revenue of $284M misses by $8.59M
Acadia Pharma press release (ACAD): Q4 GAAP EPS of $1.60 beats by $1.46. Revenue of $284M (+9.4% Y/Y) misses by $8.59M.
Acadia Pharma Q4 2025 Earnings Preview
Acadia Pharma (ACAD) is scheduled to announce Q4 earnings results on Wednesday, February 25th, after market close. The...
Acadia updates 2025 guidance, targets over $1B in revenue as DAYBUE and NUPLAZID reach milestone growth
Earnings Call Insights: ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Catherine Owen Adams, CEO, reported "another strong...
Acadia Pharma GAAP EPS of $0.42 beats by $0.28, revenue of $278.6M beats by $2.06M
Acadia Pharma press release (ACAD): Q3 GAAP EPS of $0.42 beats by $0.28. Revenue of $278.6M (+11.3% Y/Y) beats by $2.06M....
Acadia Pharma Q3 2025 Earnings Preview
Acadia Pharma (ACAD) is scheduled to announce Q3 earnings results on Wednesday, November 5th, after market close. The...
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
Acadia Pharma (NASDAQ:ACAD) shares fell in the premarket on Wednesday after the biotech announced that its experimental...
Acadia raises 2025 NUPLAZID guidance to $665M–$690M as DAYBUE accelerates community uptake
Earnings Call Insights: ACADIA Pharmaceuticals (ACAD) Q2 2025 Catherine E. Owen Adams, CEO, stated that "Our second quarter...
Acadia Pharma Q2 2025 Earnings Preview
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 6th, after market close. The...
Acadia Pharma GAAP EPS of $0.16 beats by $0.03, revenue of $264.6M beats by $2.6M
Acadia Pharma press release (NASDAQ:ACAD): Q2 GAAP EPS of $0.16 beats by $0.03. Revenue of $264.6M (+9.4% Y/Y) beats by...